Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
Autor: | Bio Joo, Joong Bae Ahn, Sang Joon Shin, Myeong-Jin Kim, Mi-Suk Park, Yeo Eun Kim |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
Male Vascular Endothelial Growth Factor A 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Bevacizumab Colorectal cancer Contrast Media Kaplan-Meier Estimate Disease-Free Survival Colorectal neoplasms Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine FOLFOX Dynamic contrast enhanced-magnetic resonance imaging Internal medicine Biomarkers Tumor medicine Humans Aged Placenta Growth Factor medicine.diagnostic_test business.industry Interleukin-8 Liver Neoplasms Hazard ratio Magnetic resonance imaging Middle Aged medicine.disease Magnetic Resonance Imaging Vascular endothelial growth factor 030104 developmental biology chemistry 030220 oncology & carcinogenesis Biomarker (medicine) Female Original Article business medicine.drug |
Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
ISSN: | 2005-9256 1598-2998 |
Popis: | Purpose The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. Results The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found. |
Databáze: | OpenAIRE |
Externí odkaz: |